Difference between revisions of "Pentraxin 2 (PRM-151)"
Jump to navigation
Jump to search
m |
m |
||
| Line 14: | Line 14: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Myelofibrosis medications]] | + | [[Category:Myelofibrosis medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 13:35, 25 February 2023
General information
Class/mechanism per NCI Drug Dictionary: A fully recombinant form of the human pentraxin 2 (PTX2) protein with potential antifibrotic activity. Upon intravenous administration, recombinant human serum amyloid P/pentraxin 2 (PRM-151) may inhibit myofibroblast generation by preventing the differentiation of circulating monocytes into fibrocytes and profibrotic macrophages. PTX2 is a circulating plasma protein that belongs to the class of pattern recognition receptors (PRR) of the innate immune system.
Route: IV
Extravasation: n/a
Preliminary data
Myelofibrosis
Also known as
- Code name: PRM-151